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ABSTRACT
Background and Aim Buprenorphine (BUP) maintenance treatment for opioid use disorder (OUD) begins with super-
vised daily dosing. We estimated the clinical effectiveness of a novel incentivised medication adherence and abstinence
monitoring protocol in BUP maintenance to enable contingent access to increasing take-home medication supplies.
Design Two-arm, single-centre, pragmatic, randomised controlled trial of outpatient BUP maintenance, with
during-treatment follow-ups at 4 weeks, 8 weeks, 12 weeks and 16 weeks. Setting Inpatient and outpatient addictions
treatment centre in the United Arab Emirates. Participants Adults with OUD, voluntarily seeking treatment.
Interventions The experimental condition was 16weeks BUPmaintenance with incentivised adherence and abstinence
monitoring (I-AAM) giving contingent access to 7-day, then 14-day, then 21-day and 28-day medication supply. The con-
trol, treatment-as-usual (TAU) was 16 weeks BUP maintenance, with contingent access to 7-day then 14-day supply.
Measurements The primary outcome was number of negative urine drug screens (UDS) for opioids, with
non-attendance or otherwise missed UDS, imputed as positive for opioids. The secondary outcome was retention in treat-
ment (continuous enrolment to the 16-week endpoint). Findings Of 182 patients screened, 171 were enrolled and 141
were randomly assigned to I-AAM (70 [49.6%]) and to TAU (71 [50.4%]. Follow-up rates at 4 weeks, 8 weeks, 12 weeks
and 16 weeks were 91.4%, 85.7%, 71.0%, 60.0% respectively in I-AAM and 84.5%, 83.1%, 69.0%, 56.3% in TAU. By
intention-to-treat, the absolute difference in percentage negative UDS for opioids was 76.7% (SD = 25.0%) in I-AAM
versus 63.5% (SD = 34.7%) in TAU (mean difference = 13.3%; 95% CI = 3.2%–23.3%; Cohen’s d = 0.44; 95% CI =
0.10–0.87). In I-AAM, 40 participants (57.1%) were retained versus 33 (46.4%) in TAU (odds ratio = 1.54; 95% CI =
0.79–2.98). Conclusions Buprenorphine maintenance with incentivised therapeutic drug monitoring to enable contin-
gent access to increasing take-homemedication supplies increased abstinence from opioids compared with buprenorphine
maintenance treatment-as-usual, but it did not appear to increase treatment retention.
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INTRODUCTION
Opioid use disorder (OUD) is a global public health
problem associated with a high disease burden [1].
Retention-oriented medication maintenance treatment
with methadone or buprenorphine (BUP), or combined
BUP and naloxone, are the first-line pharmacotherapies.
Patients who engage in OUD treatment have a marked
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reduction in overdose mortality and use of opioids [2,3].
However, many patients struggle to adhere to treatment
and discontinue prematurely. In a systematic review of
four randomised controlled trials (RCT) and 63 observa-
tional studies (294 592 participants in total), the median
retention rate was approximately 57% at 12 months [4].
Non-adherent patients are substantially more likely to re-
lapse to opioid use [5].
Driven by safety concerns, national clinical guidelines
for OUD maintenance treatment recommend that pa-
tients should receive all, or the majority of their medica-
tion, by supervision for several months, with access to
take-home supplies (to a typical maximum of 14-days
at a single dispensing event) granted to those who can
attend and take their medication as directed [6,7]. Clini-
cians favour access to unsupervised dosing for adherent
patients [8,9] and it would appear that most patients en-
dorse this as well [10]. Some patients believe supervised
dosing is stigmatising and this may motivate the decision
to leave treatment [11].
Typically, prescription adherence during OUD mainte-
nance treatment is monitored through a combination of
non-attendance alerted by the dispensing pharmacy and
monitoring of point-of-care urine drug screening (UDS)
at the clinic. The UDS is a qualitative test that gives an in-
dication of recent medication use (at a level of detection
sensitivity) but it cannot showwhether the prescribed dose
has been taken as prescribed. There have been several clin-
ical effectiveness studies of supervised and unsupervised
dosing. A meta-analysis of six such studies in methadone,
BUP and combined BUP and naloxone maintenance (four
RCTs and two prospective observational cohort studies;
7999 participants in total) judged that there was insuffi-
cient evidence for a robust difference in retention (relative
risk = 0.99, 95% CI = 0.88–1.12); or endpoint abstinence
(67% vs 60%); or medication diversion (5% vs 2%) [12].
However, the quality of these studies was rated as ‘low–
very low’, thus further evidence is likely to change this
conclusion.
Is there a better way to monitor adherence during
BUP maintenance and help patients receive increasing
take-home supplies? One promising set of procedures is
therapeutic drug monitoring (TDM). TDM is defined as
the ‘quantification and interpretation of drug concentra-
tions in blood to optimize pharmacotherapy’ [13]. Clinical
applications involve repeated measurements of the
plasma concentration of a medicine to reach a dose that
is well tolerated, minimises the risk of adverse drug reac-
tions and achieves the desired effect. Unlike UDS, TDM
can provide a precise indication that medication has been
taken as directed. Two decades ago, TDM was predicted
to become the standard-of-practice for OUD maintenance
pharmacotherapy [14]. However, TDM has not been
implemented to any significant extent, and there have
been no trials applying TDM procedures during BUP
maintenance.
Accordingly, this study is a contribution toward closing
this gap. As a precursor, we optimised a laboratory
quantification method for BUP monitoring, demonstrating
that this was feasible during routine clinical operations
[15]. Including TDM procedures, we developed a novel
incentivised medication adherence and abstinence moni-
toring (I-AAM) protocol. The aim of I-AAM was to enable
BUP dose-optimised patients who could provide ongoing
evidence of adherence and abstinence from opioids, access
to increasing take-home supplies of their medication. The
aim was to estimate the clinical effectiveness of BUP main-




The study was done at the inpatient and outpatient service
of the National Rehabilitation Centre (NRC), Abu Dhabi,
United Arab Emirates (UAE). The NRC is the only national
provider of BUP maintenance treatment in the UAE. The
centre receives referrals frommetropolitan Abu Dhabi with
50% of patients attending from other cities and remote
areas. In the UAE, heroin, morphine and tramadol are
the most common illicit and non-medical prescription
opioids reported by populations with OUD. Locally, BUP is
not available at community retail pharmacies, so medica-
tion is dispensed by the NRC’s outpatient pharmacy.
The NRC commenced BUP maintenance treatment in
2002. Patients who took their medication as directed and
were abstinent from opioids received up to 14-days take-
home supply (this limit set by the centre’s dispensing
policy). A decade later, and in the context of anecdotal
reports of BUP diversion and non-adherent dosing behav-
iours among some patients, the NRC suspended treatment
for people with no treatment history of BUP maintenance,
although granting maintenance treatment to new patient
episodes enrolled in this study.
Design
This was a single-centre, two-arm, open-label, parallel
group, pragmatic RCT of BUP I-AAM (the experimental
group) versus BUP TAU (the control group) during
16-weeks of outpatient maintenance treatment. During-
treatment follow-ups were at 4 weeks, 8 weeks, 12 weeks
and 16 weeks. The NRC’s Institutional Review Board
approved the protocol (NRC/2/2014). The study was retro-
spectively registered with the ISRCTN registry (number
ISRCTN416 45 723) and the study protocol was published
[16]. In this article, methods and findings are reported by
Consolidated Standards of Reporting Trials (CONSORT)
Incentivised adherence and abstinence monitoring in buprenorphine maintenance 2399
© 2021 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction, 116, 2398–2408
[17]. Medicationmanagement and other participantmate-
rials can be access on the Open Science Framework
(https://osf.io/t9rp4/quickfiles).
The study was conducted in accordance with the ethi-
cal principles of the World Medical Association’s Declara-
tion of Helsinki for research involving human subjects,
good clinical practice and the Abu Dhabi Department of
Health’s guidelines for medical research. Study partici-
pants received study medication without charge and did
not receive any compensation for completing research
measures. After participants completed the study, they
continued to receive BUP maintenance according to their
preference and clinic policy.
Contingent on evidence of adherence (attendance and
contrasting BUP measured and concentrations) and absti-
nence (from opioids by UDS), participants allocated to the
I-AAM condition had access to increasing take-home sup-
plies of BUP. Dispensing increased from 7 days, to 14 days,
to 21 days to a maximum of 28 days supply. Participants
allocated to TAU had no blood testing for BUP concentra-
tionmeasurement and had access to a 7 days then 14 days
maximum.
An online randomisation service (www.randomization.
com) was used to allocate participants to the two groups
(1:1; no stratification). Given the open-label design, it was
not feasible to mask participants and study investigators.
A planned, exploratory health economic analysis will be re-
ported elsewhere.
Inpatient withdrawal management and BUP stabilisation
At the NRC, medically supervised opioid withdrawal and
BUP dose induction is done at an onsite inpatient pro-
gramme before outpatient treatment. During inpatient
stay, dose stabilisation was carried out with the objective
of settling on a maintenance dose that was personalised
for each participant informed by signs and symptoms of
opioid withdrawal and their feedback.
Outpatient maintenance medication treatment
Participants were maintained on BUP-naloxone (4:1) sub-
lingual film formulation (Suboxone; Indivior; BUP herein).
This product was developed to limit risk of diversion and
dissuade injection. All medication was bought commer-
cially. The outpatient maintenance treatment endpoint
was 16 weeks (112 days). This was pragmatic and judged
reasonable to estimate clinical benefit. During treatment,
all participants were offered general counselling and case
management support.
For each scheduled clinic visit, the participant was
asked to return opened medication packaging and take a
UDS test. We used commercial point-of-care UDS product
(https://www.cliawaived.com). The test cup was
configured to detect morphine (detection limit 300 ng/
mL), heroin (6-acetylmorphine 20 ng/mL), codeine
(100 ng/mL), propoxyphene and hydrocodone (300 ng/
mL), tramadol (200 ng/mL), oxycodone (100 ng/mL),
fentanyl (1000 ng/mL) and BUP (10 ng/mL). With the
exception of BUP, all test results were required to be nega-
tive for the UDS to be recorded ‘opioid negative’. All positive
opioid test results were confirmed by gas chromatography
tandem mass spectrometry.
Study participants
Participants were adults (18 years and over). All had
current OUD and voluntarily seeking treatment (Table 1
shows the inclusion and exclusion criteria). Consecutive
referrals were screened in person and all participants pro-
vided their informed written consent. All adverse events
were reviewed by the senior investigators and the data
monitoring committee.
Study procedures
After enrolment, participants were admitted to the NRC’s
onsite inpatient service for up to 4 weeks for medically
supervised withdrawal, BUP induction and dose stabiliza-
tion. As soon as they were comfortable, participants com-
pleted a structured interview recording demographic
characteristics and baseline measures. Each participant
was administered BUP daily under supervision at the same
time. In an effort to personalise each participant’s dosing
Table 1 Participant inclusion and exclusion criteria.
Inclusion criteria
1. Aged 18 and above (no upper limit)
2. Current diagnosis of OUD
3. Voluntarily seeking BUP maintenance treatment
4. Resident in the UAE
5. Evidence of stable accommodation
Exclusion criteria
1. Benzodiazepine use in excess of 20 mg/day daily diazepam
equivalent in the past 28 days
2. Known naloxone or BUP hypersensitivity
3. Pregnancy
4. Hepatic impairment (elevation of liver function tests three
times normal)
5. Suicide attempt in past 12 months
6. Involvement in criminal justice system, which is likely to
result in arrest and incarceration
7. Uncontrolled severe mental or physical illness judged to
compromise safety
8. Mini Mental State Examination score <17 (indicating
cognitive dysfunction)
OUD = opioid use disorder; UAE = United Arab Emirates; BUP =
buprenorphine.
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interval, those who consumed illicit opioids by an injection
(or with a body mass index of 30 and polysubstance use)
commenced daily dosing. Those with prescription OUD
were recommended to receive alternate-day dosing (i.e. ev-
ery 48 hours). Our protocol also included the option for
this patient group to attempt stabilisation with thrice-
weekly dosing (to the dose maximum of 32 mg/day).
Alongside patient preference, clinical signs and symptoms
(using the Clinical Opiate Withdrawal Scale [COWS])
[18]; pupil reflexes (https://www.neuroptics.com) and
craving using the Minnesota Cocaine Craving Scale
adapted for opioids (MCCS-O; scored: 0–100%) [19] in-
formed decisions about commencing, achieving a dosing
interval or reverting to a more frequent dosing interval.
When the participant was comfortably stable on the
same BUP dose for 2 weeks, we assumed BUP’s
steady-state concentration had been achieved. An on-site
laboratory, computed the BUP elimination rate (EL.R) from
three blood samples; the first drawn 30 minutes before ad-
ministration of the participant’s BUP dose (to estimate the
BUP trough concentration), the second drawn after 40mi-
nutes (peak concentration), and the third after 48 hours
before the next BUP dose (for a second trough concentra-
tion to confirm steady-state concentration if replicated).
The inpatient episode was then judged completed once
the EL.R had been calculated and the participant had a
COWS score of 0–4 (no active opioid withdrawal). Before
transfer to the outpatient programme, a member of the
study team accessed the randomisation service and the
participant was allocated to the I-AAM or TAU condition.
I-AAM procedure and take-home dosing schedule
1 For the first 5 days of BUP maintenance treatment, the
participantwas asked to attend the clinic daily for super-
vised dosing and to take a UDS test at each visit (or a
minimum of three UDS). If they adhered (i.e. all doses
taken, at least three negative UDS and all UDS positive
for BUP), participants were dispensed with two doses
to take that weekend and a 7-day supply. They were
given instructions on how to take their medication (i.e.
daily, alternate-day and thrice weekly regimens) and
asked to return to the clinic 1 week later.
2 If participants returned as directed, reported following
their prescription, and gave an opioid negative UDS that
was positive for BUP, they were dispensed with a 14-day
supply. Participants were asked to not take their BUP
dose on the day of their next appointment because this
was given by the dispensing pharmacy. On arrival, they
were given their dose of BUP, they took a UDS and had a
blood sample drawn. A pharmacokinetic model was ap-
plied to predict BUP concentration [15]. If the UDS con-
firmed abstinence for opioids and was positive for BUP,
the participant was given a further 14-day supply (with
same directions) and asked to return to the clinic
2 weeks later.
3 On return to the clinic, the procedure was repeated and
the predicted BUP concentration (estimated from the
previous visit) was contrasted with the BUP concentra-
tion on the day. If the concentration difference was
<20% and the UDS was negative, participants were
given a 21-day supply and asked to return 3 weeks later.
As a safety measure, participants given a 21-day supply
were contacted randomly and asked to attend for UDS
and blood testing.
4 On return to the clinic, and with evidence of continued
adherence and clinical benefit (i.e. difference in BUP
concentration <20%; UDS negative), participants were
given a 28-day supply and asked to return 1month later
for a further monthly supply. Adherence and abstinence
were then randomly monitored every other month to
the endpoint.
Those not adhering to the above procedure at the outset or
for the requirements of the 7-day supply were held at a
5-day supervised dosing requirement pending evidence of
adherence and abstinence. Those receiving 14 days who
were non-adherent or non-abstinent were ‘reset’ to receive
a 7-day supply. Those receiving a 21-day and 28-day sup-
ply that were non-adherent or non-abstinent were reset
to a 14-day or 21-day supply, respectively. At any point, a
participant who was non-adherent and non-abstinent
was held in a 5-day supervised dosing and UDS testing reg-
imen. During this process, patients discussed their scores
on the COWS (weeks 1–4), and MCCS-O (weeks 1–4 and
5–8), and pupil reflexes (weeks 5–8 and 13–16) and asked
if they wanted their dose adjusted.
TAU procedure and take-home dosing schedule
1 In the first 5 days of maintenance, participants were
asked to attend the clinic at least once for supervised
BUP dosing and to take a UDS at each visit. Between
visits participants were dispensed with take-home doses.
If they adhered (i.e. all doses taken, all UDS-negative and
all UDS-positive for BUP), they were dispensed with a
7-day supply including 1 dose to take on each day of
weekend. Participants were given instructions on how
to take their medication (i.e. daily, alternate-day and
thrice weekly regimens) and asked to return to the clinic
1 week later.
2 If participants returned, reported following their pre-
scription, and provided an opioid negative UDS that
was positive for BUP, they were dispensed with a
14-day take-home supply.
Participants who did not adhere to the above procedure at
the outset or for the requirements of the 7-day supply, were
held in 5-day supervised dosing (with 2 take-home doses
for the weekend) until there was evidence of abstinence.
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At any point, a participant who was non-adherent and
non-abstinent was reset to 5-day supervised dosing and
UDS testing. During treatment, there was discussion of
withdrawal symptoms, craving and dose adequacy, as
described above for the experimental group.
Table S1 summarizes the Interventions under each
arm.
Outcome measures
The primary outcome was the number (percentage) of
scheduled and biochemically verified (UDS and laboratory
confirmed) tests negative for opioids during 16 weeks of
outpatient BUP maintenance treatment. Conservatively,
non-attendance for scheduled UDS was recorded as posi-
tive for opioids [20]. The secondary outcome measure
was retention in outpatient treatment, defined as comple-
tion of 16 weeks of treatment (with no more than three
missed consecutive clinic appointments).
The five exploratory outcome measures (end-of-study
group comparison), were; The Addiction Severity Index-
Lite—drug use sub-scale (ASI-Lite) [21], the nine-item Pa-
tient Health Questionnaire (PHQ-9) [22], the Generalized
Anxiety Disorder scale (GAD-7) [23], the Barratt Impulsiv-
ity Scale (BIS-11) [24] and the Work and Social Adjust-
ability Scale (WSAS; score range = 0–40; higher scores
reflecting more social impairment attributed to OUD)
[25]. No changes were made to the outcomes after the
trial commenced.
Statistical analysis
To guide the target sample size, we used a measure of
sustained (3-week) abstinence between treatment and
comparison groups in a meta-analysis of incentivised
OUD treatment (44% vs 23%; OR 1.96) [26]. With type I
error at 5%, and a 15% increase in the sample to offset
withdrawal attrition, we estimated that 182 participants
(91 in each group) would give 80% statistical power for
detection of a treatment effect.
The analysis was done by intention-to-treat in Stata 15
(Statacorp 2017). The primary outcome was analysed as
the absolute difference in the percentage of negative UDS
tests for opioids, reporting themean and SD for each group,
the mean difference on this measure with a 95% CI; and
the Cohen’s d effect size with a 95% CI.
There were two sensitivity checks: (1) an adjusted
treatment effect estimated by a bootstrapped Poisson re-
gression (incident rate ratio [IRR]) with the following
covariables: age, baseline ASI-Lite drug use, and (2) time
(days) to discontinuation or completion of treatment. We
also calculated the primary outcome as a complete case
measure using only observed (non-imputed) UDS data.
The secondary outcome measure was analysed by Odds
Ratio (OR) and Kaplan-Meier test. Exploratory outcomes
were analysed by group mean difference at the study
endpoint. The incidence of all adverse events was reported
for both study groups.
RESULTS
Characteristics of the participants
The first participant was enrolled on 15 September
2014 and the last follow-up contact was on 16 Septem-
ber 2016. The trial database was locked on 19 January
2017. A total of 182 patients were screened for eligibil-
ity and 171 were enrolled into the study. Thirty partici-
pants (17.5%) withdrew before randomisation and 141
(82.4%) were randomised (70 [49.6%] to the I-AAM
group and 71 [50.4%] to the TAU group. Figure 1
shows the study profile and reasons for exclusion. We
were unable to extend the participant recruitment phase
because of restrictions on the time permitted for the
study.
On admission to the inpatient service, the majority
of participants received daily dosing at the outset, with
just four accepting our recommendation for alternate-
day dosing. A single participant was inducted onto
thrice-weekly dosing. The two groups were well-balanced
on demographic and clinical characteristics (upper section
of Table 2). After randomisation, all participants were
transferred to commence BUP maintenance at the outpa-
tient clinic. In the first week, 16 participants left treatment
(six in the I-AAM group and ten in the TAU group).
Between randomisation and the endpoint, a total of 30
(42.9%) participants in the I-AAM group and 38 (53.5%)
participants in the TAU group discontinued treatment. All
participants agreed to take UDS, provide blood samples,
return opened BUP packaging and all consented for their
data to be used for the analysis. Follow-up rates at 4 weeks,
8 weeks, 12 weeks and 16 weeks were 91.4%, 85.7%,
71.0%, and 60.0%, respectively, in the I-AAM group and
84.5%, 83.1%, 69.0% and 56.3%, respectively, in the
TAU group.
BUP maintenance treatment
Table 2 (lower section) shows the mean BUP dose for the
participants retained at each follow-up week and their ac-
cess to take-home supplies. On average, the BUP dose was
15 mg/day in the I-AAM group and 16 mg/day in the
TAU group at each follow-up. Almost all study participants
remained on their stabilisation dose during maintenance
(138/141; 97.9%).
Three participants increased their dose, as follows:
after 3 weeks, a participant in the I-AAM group reported
distressing craving and informed by measures of pupil
reflexes (particularly measures of maximum pupil
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diameter) their dose was increased from 14–16 mg/day;
a TAU participant—with a long history of tramadol use
—reported opioid withdrawal symptoms in the second
week of treatment and dose was increased from 12–
14 mg/day; the other participant—a member of the
TAU condition—had presented for treatment with severe
OUD involving intravenous use of morphine and trama-
dol—reported craving and withdrawal symptoms during
the second week of treatment and dose was increased
from 12–16 mg/day.
During treatment, 18 participants in the I-AAM group
(29.0%) were determined to be non-adherent to BUP and
non-abstinent. All were reset to 5-day supervised dosing.
Among 62 participants in the I-AAM group who received
at least one 14-day supply of medication, a total of 109
blood samples were drawn with 37 samples estimated to
have BUP concentrations outside the 20% range for adher-
ence (33.9% non-adherent). In the TAU group, 20 partici-
pants (28.2%) were able to receive no more than a total of
7-day take-home doses, and 51 (71.8%) received no more
than a 14-day take-home supply.
In the I-AAM group, among 62 participants who re-
ceived at least 2 weeks take-home supply, 109 blood
samples were drawn (mean 1.8 [SD 0.77] per participant).
The non-adherence ratewas 34% (i.e. 37 samples had BUP
concentrations outside the 20% range). Eighteen partici-
pants in the I-AAM group (29.0%) were evaluated as
BUP non-adherent and non-abstinent and were reset to
5-day directly supervised dosing.
In the TAU group, 20 participants (28.2%) received
no more than 7-day take-home doses, and 51 (71.8%)
received no more than 14-day take-home doses. There
was no statistically significant difference in the mean
number of scheduled UDS: 16.2 (SD = 9.0) in the
I-AAM group versus 14.1 (SD = 8.9) in the TAU group
(P value = 0.10).
During treatment, participants in both groups returned
opened BUP packaging to the pharmacy very sporadically.
Patients failing to return opened packaging were reminded
to do so, but full compliance was rare. In the group of
participants completing the 16 weeks of maintenance
treatment, 1 participant in the I-AAM group was fully
adherent according to TDM data and remained abstinent;
17 (42.5%) were adherent, but not abstinent. Among the
non-adherent, 18 (45.0%) were also non-abstinent, and
4 (10.0%) were abstinent.
Figure 1 Study profile
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Primary outcome
Although the obtained sample was smaller that was
targeted (post-study sample size calculation using the ex-
pected effect and obtained sample size indicated that statis-
tical power was 75%), there was a statistically significant
effect for the I-AAM condition on the primary outcome
(Table 3).
For the two sensitivity analyses, I-AAM effectiveness
(including age, baseline ASI-Lite drug use and time to dis-
continuation or completion of treatment) was observed
(adjusted IRR = 1.15; 95% CI = 1.02–1.32), and using
Table 2 Participant characteristics (n = 141).
Characteristic I-AAM (n = 70) TAU (n = 71)
Demographic and clinical characteristics at baseline 30.4 (8.70) 27.7 (7.30)
Age, years
Sex, male 69 (98.6%) 70 (98.6%)
Married 36 (51.4%) 46 (63.3%)
Employed, full or part-time 28 (40.0%) 21(29.6%)
Resident in metropolitan Abu Dhabi 36 (52.8%) 30 (42.2%)
Heroin/morphine OUD 55 (78.6%) 55 (77.5%)
Prescription/mixed OUD 15 (21.4%) 16 (22.5%)
Duration of OUD, median years 9.9 (5.7–17.3) 8.9 (5.4–14.7)
MCCS-O, maximum intensity in week before admission 88.6% (23.7%) 83.9% (31.5%)
ASI (drug use scale score) 0.2 (0.1–0.4) 0.2 (0.1–0.4)
PHQ-9 12.9 (6.6) 13.6 (6.9)
GAD-7 10.0 (4.0–15.0) 10.0 (5.0–15.0)
WSAS 22.1 (9.8) 24.2 (9.2)
Inpatient withdrawal and stabilisation (ng/mL)
BUP trough concentration after 2 weeks—mean 1.73 (1.47) 1.81 (2.47)
EL.R before transfer to outpatient treatment—median 0.05 (0.03–0.09) 0.05 (0.02–0.10)
Maintenance treatment week—BUP dose (mg/day)a
Week 1 14.51 (4.63) 15.71 (3.60)
Week 4 14.68 (4.58) 15.60 (3.51)
Week 8 15.08 (4.50) 15.72 (3.52)
Week 12 15.02 (4.57) 15.72 (3.58)
Week 16 14.75 (4.45) 15.36 (3.22)
Take-home supplies (total dispensing events)
No more than 7 days 1 (1) 20 (20)
No more than 14 days 55 (402) 51 (387)
No more than 21 days 7 (81)b –d
No more than 28 days 1 (8)c –d
I-AAM = BUP maintenance treatment with incentivised adherence and abstinence monitoring; TAU = BUP maintenance treatment-as-usual; OUD = opioid
use disorder; MCCS-O, Minnesota Cocaine Craving Scale, adapted for opioids, maximum intensity in week before admission (0–100%); PHQ-9 = Patient
Health Questionnaire; GAD-7 =Generalized Anxiety Disorder;WSAS =Work and Social Adjustability Scale; ASI-Lite = Addiction Severity Index; EL.R= elim-
ination rate (ng × mL/hr 1). Numbers in parentheses = SD, interquartile range, or as shown. aAll participants enrolled at follow-up. bFive participants were
dispensed this supply once and two each received this supply twice.
c
This participant received two successive 21-day supply before the single 28-day supply.
d
Prohibited under local treatment system policy.
Table 3 Summary of scheduled and imputed urine drug screen tests and primary outcome measure (n = 141).
Measure I-AAM (n = 70) TAU (n = 71)
UDS testing
A. Mean number of scheduled UDS (SD) 16.2 (9.0) 14.1 (8.9)
B. Mean number of UDS positive for opioids (SD) 1.0 (1.8) 1.9 (3.2)
C. Mean number of UDS, missed, imputed positive (SD) 2.3 (2.4) 2.2 (2.4)
Efficacy
Primary outcome measurea 76.7% (25.0%) 63.5% (34.7%)
Mean difference (95% CI) 13.3% (3.2%–23.3%)
d (95% CI) 0.44 (0.10–0.87)
I-AAM = incentivised adherence and abstinence monitoring; TAU = treatment-as-usuale; UDS, urine drug screen.
a
Computed as A B + C)/(A × 100) (SD).
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observed UDS data only, the percentage of UDS negative for
opioids was 90.5% (SD = 19.8%) in the I-AAM group and
71.8% (SD = 36.7) in the TAU group (mean difference
18.7%; 95% CI = 8.9–28.5; d = 0.63; 95% CI = 0.29–
0.97). There was no statistically significant difference in
the mean number of scheduled UDS tests (16.2 [SD =
9.0] in the I-AAM group versus 14.1 [SD = 8.9] in the
TAU group; P value = 0.10).
Secondary outcome
Forty participants (57.1%) in the I-AAM group were
retained continuously in maintenance treatment to the
endpoint versus 33 participants (46.4%) in the TAU group
(OR = 1.54; 95% CI = 0.79–2.98). The I-AAM group was
retained for a mean of 81.7 days (SD = 42.3), and TAU par-
ticipants were retained for a mean of 76.6 days (SD = 39.9;
mean difference 5.1 days; 95% CI = 8.6–18.8). Figure 2
displays a survival chart for time-to-discontinuation by
group (log rank test P value = 0.26).
Exploratory outcomes
End-of-study group differences on the exploratory outcome
are shown in the article’s supplementary material
(Supporting information Table S2). There was an I-AAM
effect on the WSAS indicating less social impairment
associated with OUD at the endpoint (a 6-point mean dif-
ference; Cohen’s d = 0.53; 95% CI = 0.19–0.87).
Adverse events
There were no serious adverse events requiring
hospitalisation and there was a similar profile of adverse
events in both groups (Supporting information Table S3).
The adverse event with the highest reported incidence
was sweating. This was rated severe by three participants
in the I-AAM group and four participants in TAU group
and judged to have a possible association with BUP.
DISCUSSION
In the I-AAM group, slightly more participants achieved
dispensing of 14 days supply compared with TAU (55 vs
51). Within the I-AAM group, a minority achieved
dispensing supplies above this; seven receiving dispensing
of 21 days supply and one attaining maintenance dispens-
ing of 28 days supply. In terms of the primary outcome,
there was significant variability between the two groups,
but we believe that the I-AAM condition was associated
with a clinically important effect. There was a single ex-
ploratory outcome on the WSAS suggested that I-AAM
participants had the additional benefit of fewer social
problems attributed to OUD.
Although the randomisation procedure did not include
any stratification, the sensitivity including patient demo-
graphic, baseline drug use and time in treatment showed
an adjusted treatment effect that was statistically signifi-
cant. Furthermore, comparison of the conservatively
imputed versus observed primary outcome measure
(13.3% vs 18.7%, respectively), suggests that true effect
for I-AAM is bracketed within these two estimates.
Nevertheless, there remains considerable scope to increase
clinical effectiveness. Among participants in the I-AAM
group who completed 16 weeks of treatment, 22 (55%)
were completely adherent. This is comparable to an Aus-
tralian surveillance study, where a third of patients enrolled
in BUP-naloxone maintenance did not adhere and 34
(85%) of those who stayed in treatment did not abstain
from opioids [27].
In the present study, I-AAM was not significantly
associated with a higher rate of completion for the
16-week active treatment period or duration of enrolment
(57% vs 46%). These rates are comparable with other
studies of BUP maintenance. For example, in a United
States dose comparison trial over 16 weeks of BUP mainte-
nance, completion rates were 52% for patients receiving
8 mg/day, and 61% for those allocated to 16 mg/day
[28]. Another United States trial of 17 weeks of mainte-
nance treatment reported a 58% completion for patients
receiving higher-doses of 16–32 mg/day [29].
Figure 2 Survival analysis for retention over
16 weeks (log-rank P value = 0.26). BUP =
Buprenorphine; I-AAM = incentivised adher-
ence and abstinence monitoring; TAU =
treatment-as-usual. [Colour figure can be
viewed at wileyonlinelibrary.com]
Incentivised adherence and abstinence monitoring in buprenorphine maintenance 2405
© 2021 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction, 116, 2398–2408
Study limitations
Our findings must be considered in the light of several lim-
itations. First, the sample was 23% smaller than planned
so the analyses had reduced statistical power by 5%. The
study took longer to complete than we envisaged because
of a lower rate of recruitment. During the recruitment
phase there was a reduction in opioid use in the UAE and
an increase in amphetamine-type stimulant use [30]. This
may have reduced OUD treatment demand.
Second, the sample was almost exclusively male, with
just two female participants. We had no control over the
referral process, and it remains an important priority to
study sex as a factor in OUD treatment delivery and
outcomes [31].
Third, the BUP induction and stabilisation was done in
an inpatient facility that is typically available in the
healthcare systems in UAE and states in the Eastern
Mediterranean, but dose induction is most commonly done
in an outpatient setting elsewhere. A 24-hour medically
supervised setting makes it more convenient to collect
blood samples, but our discontinuation rate in this phase
of the study (30/171; 17.5%) was comparable to the dis-
continuation rate reported for an 8-day outpatient study
in Australia (14% for patients assigned to BUP for with-
drawal management) [32]. We contend that where outpa-
tient services are based in locations with reasonably good
local transport options, collection of three blood samples
for BUP EL.R should be acceptable to most patients.
Clinical and research importance of the findings
The I-AAM protocol included a quantitative TDM
procedure (BUP plasma concentration criterion) to moni-
tor adherence. TDM procedures to inform changes in
maintenance dosing were rarely used with the majority
of the group remaining on their stabilisation dose. We also
found that almost all participants accepted daily dosing.
It is important to consider how the primary and second-
aryoutcomes were defined in this study. At present, there is
no common outcome set for OUD pharmacotherapy trials.
It is not uncommon to define the primary outcome as a
count of consecutive negative UDS. This can give valuable
insight into periods of stability. This was a pragmatic and
study among patients who presented for treatment as
usual, so we believe our findings are generalizable. Our
I-AAM protocol has promise as a clinically effect method
helping patients access increasing supplies of take-home
medication. Relatively few participants (8/40; 20%) were
able to provide evidence of sustained adherence and absti-
nence to receive supplies above the comparator. Overall,
participants in the I-AAM condition received 20% more
take-home supplies for more or equal to 7 days (492 total
dispensing events vs 407 among the TAU group).
There remains a priority need to discover better ways of
encouraging patients to stay in optimised treatment.
Although efforts to increase retention are crucial, it should
be recognised that retention is a proxy measure of clinical
benefit because some patients stay in treatment but con-
tinue to use opioids. This has been observed in other treat-
ment systems. For example, in an English national study of
12 745 patients enrolled for 12–26 weeks in OUD mainte-
nance pharmacotherapy, 64% reported using opioids on
10 or more days in the month before follow-up [33]. One
option is to include an adjunctive psychosocial interven-
tion targeting patients who struggle to adhere or abstain
[33]. Extended-release (depot injection) BUP products are
now becoming increasingly available and this may reduce
concerns about diversion and provide potential opportuni-
ties to apply TDM for dose optimisation during stabilisation
and dose adjustment during maintenance.
Although we had direct access to a clinical toxicology
laboratory, it typically took 48 hours to process blood sam-
ples and receive test results for BUP plasma levels. This was
longer than anticipated and it did hamper our efforts to
make timely clinical decisions with study participants. In
other areas of psychiatry, there is active research and devel-
opment on non-invasive technologies such as small, porta-
ble sensing or test strips for capture of capillary blood to
detect antipsychotic medication concentration [34]. Rapid
point-of-care diagnostics to facilitatemedication adherence
monitoring during BUP treatment would be welcome.
Monitoring BUP plasma concentration may be added to
measures of craving, drug use and withdrawal symptoms
to optimise treatment as part of measurement-based care
for OUD [35].
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